Literature DB >> 24441398

Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Carla L Esposito1, Laura Cerchia1, Silvia Catuogno1, Gennaro De Vita1, Justin P Dassie2, Gianluca Santamaria3, Piotr Swiderski4, Gerolama Condorelli5, Paloma H Giangrande6, Vittorio de Franciscis7.   

Abstract

While microRNAs (miRNAs) clearly regulate multiple pathways integral to disease development and progression, the lack of safe and reliable means for specific delivery of miRNAs to target tissues represents a major obstacle to their broad therapeutic application. Our objective was to explore the use of nucleic acid aptamers as carriers for cell-targeted delivery of a miRNA with tumor suppressor function, let-7g. Using an aptamer that binds to and antagonizes the oncogenic receptor tyrosine kinase Axl (GL21.T), here we describe the development of aptamer-miRNA conjugates as multifunctional molecules that inhibit the growth of Axl-expressing tumors. We conjugated the let-7g miRNA to GL21.T and demonstrate selective delivery to target cells, processing by the RNA interference machinery, and silencing of let-7g target genes. Importantly, the multifunctional conjugate reduced tumor growth in a xenograft model of lung adenocarcinoma. Therefore, our data establish aptamer-miRNA conjugates as a novel tool for targeted delivery of miRNAs with therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24441398      PMCID: PMC4048903          DOI: 10.1038/mt.2014.5

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles.

Authors:  Tommy Cedervall; Iseult Lynch; Stina Lindman; Tord Berggård; Eva Thulin; Hanna Nilsson; Kenneth A Dawson; Sara Linse
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-31       Impact factor: 11.205

2.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

3.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

6.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Authors:  Shawn E Lupold; Brian J Hicke; Yun Lin; Donald S Coffey
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

8.  Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.

Authors:  Xin Wu; Baoyue Ding; Jing Gao; Huanyun Wang; Wei Fan; Xiang Wang; Wei Zhang; Xiaoyu Wang; Lihua Ye; Min Zhang; Xueying Ding; Jiyong Liu; Quangang Zhu; Shen Gao
Journal:  Int J Nanomedicine       Date:  2011-08-19

9.  Targeting Axl with an high-affinity inhibitory aptamer.

Authors:  Laura Cerchia; Carla L Esposito; Simona Camorani; Anna Rienzo; Loredana Stasio; Luigi Insabato; Andrea Affuso; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

10.  Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition.

Authors:  Alexey Berezhnoy; Randall Brenneman; Marcio Bajgelman; Dawn Seales; Eli Gilboa
Journal:  Mol Ther Nucleic Acids       Date:  2012-10-16       Impact factor: 10.183

View more
  68 in total

Review 1.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

Review 2.  MicroRNAs and Periodontal Homeostasis.

Authors:  X Luan; X Zhou; J Trombetta-eSilva; M Francis; A K Gaharwar; P Atsawasuwan; T G H Diekwisch
Journal:  J Dent Res       Date:  2017-01-09       Impact factor: 6.116

Review 3.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

Review 4.  MicroRNA mediated regulation of immunity against gram-negative bacteria.

Authors:  Jonathon Keck; Rishein Gupta; Lane K Christenson; Bernard P Arulanandam
Journal:  Int Rev Immunol       Date:  2017-08-11       Impact factor: 5.311

Review 5.  Aptamers as Therapeutics.

Authors:  Shahid M Nimjee; Rebekah R White; Richard C Becker; Bruce A Sullenger
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-01-06       Impact factor: 13.820

6.  Method for Confirming Cytoplasmic Delivery of RNA Aptamers.

Authors:  David D Dickey; Gregory S Thomas; Justin P Dassie; Paloma H Giangrande
Journal:  Methods Mol Biol       Date:  2016

7.  How to train your dragon: targeted delivery of microRNA to cancer cells in vivo.

Authors:  Marcin Kortylewski; Sergey Nechaev
Journal:  Mol Ther       Date:  2014-06       Impact factor: 11.454

8.  Challenges identifying efficacious miRNA therapeutics for cancer.

Authors:  Meirav Segal; Frank J Slack
Journal:  Expert Opin Drug Discov       Date:  2020-05-18       Impact factor: 6.098

Review 9.  Manipulating the in vivo immune response by targeted gene knockdown.

Authors:  Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2015-07-03       Impact factor: 7.486

Review 10.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.

Authors:  Merve Mutlu; Umar Raza; Özge Saatci; Erol Eyüpoğlu; Emre Yurdusev; Özgür Şahin
Journal:  J Mol Med (Berl)       Date:  2016-04-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.